论文部分内容阅读
罗塞秦(Locekin)又名头孢曲松,头孢三嗪(Cefriax-one),瑞士商品名为菌必治,是第三代头孢菌素。1978年由Reiner等首先研制成功,1980年由瑞士罗氏(Roche)制药公司制成针剂,用于临床并获得了优异的疗效。深圳南方制药厂于1991年也研制成功了罗塞秦,经北京医科大学临床药理研究所、广东省人民医院、广州医学院第一附属医院等临床试验研究证实,其质量、药理作用、临床疗效均与国外同类产品相同,现已经投放市场,供临床使用。本品具有广谱、耐酶、长效、高效、低毒等特点。
Locekin, also known as ceftriaxone, ceftriaxone (Cefriax-one), the Swiss brand of bacteria will rule, is the third generation cephalosporins. In 1978, Reiner and other first successful development, in 1980 by the Swiss Roche (Roche) pharmaceutical company made injection, for clinical and obtained excellent curative effect. Shenzhen Nanfang Pharmaceutical Factory also developed Roset Qin in 1991. The clinical trial of clinical pharmacology institute of Beijing Medical University, Guangdong Provincial People’s Hospital and the First Affiliated Hospital of Guangzhou Medical College confirmed that the quality, pharmacological effect and clinical curative effect All the same with foreign similar products, is now on the market for clinical use. This product has a broad spectrum, resistant to enzymes, long-term, high efficiency, low toxicity and so on.